Pfizer Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert Bourla
- Full Time Employees
- 75,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 66 Hudson Boulevard East New York City NY United States of America 10001-2192
- IPO Date
- Jun 1, 1972
- CIK
- 0000078003
- Website
- pfizer.com
- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?
Pfizer's Bear Case Is Breaking
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Pfizer: Still Mispriced By Mr. Market (Earnings Preview)
Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
Europäische Kommission genehmigt Marktzulassung des an XFG angepassten COVID-19-Impfstoffs von Pfizer und BioNTech in der Europäischen Union
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
5 High-Yielding Dividend Stocks for Retirees to Buy and Hold Forever
Boomers Are Buying 5 Quality High-Yield Stocks at Big Discounts Hand Over Fist
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far
Gabelli Funds LLC Lowers Position in Pfizer Inc. $PFE
3 Absurdly Cheap Dividend Stocks to Buy Before August
Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' July DiviDogs